Genetic Analysis Market - By Product (Instruments, Reagents & Kits, Software), By Test (Predictive Genetic Testing, Carrier Testing, Prenatal and Newborn Testing, Disease Diagnostic Testing), By Application, Technology, By End-use & Forecast, 2022 - 2030

Genetic Analysis Market Size

Genetic Analysis Market size was valued at over USD 9.5 billion in 2021 and will exhibit more than 8% CAGR between 2022-2030. Growing incidence of genetic disorders worldwide to bolster market dynamics.
 

A genetic disorder is an extremely rare phenomenon and accounts for close to 80% of all rare disorders. Estimates reveal that close to 7.9 million children are born with acute birth defects every year. These defects are either partially or entirely genetic in nature. Some of the genetic disorders include cystic fibrosis, sickle cell anemia, Tay-Sachs, turner syndrome, Fragile X syndrome, and hemochromatosis.
 

Every year, more than 300,000 babies are born with sickle cell anemia in the world, with the number projected to rise to over 400,000 by 2050. The prevalence of this disorder is observed in developing economies like India, the Middle East and Africa, where over 40% of the population is said to be affected. Over 90% of SCD-affected children from third-world nations do not survive till adulthood. This growing prevalence of genetic disorders across emerging economies will thus fuel industry trends.
 

High costs of genetic testing may hamper the market growth to a certain extent. Based on the complexity and type of the test, the cost of genetic testing varies from USD 100 to over USD 2,000 per test. The prices further rise if multiple family members are required to be tested or multiple tests are required to obtain accurate outcomes. Tests that are misordered and provide false reassurance breach the clinical practice regulations as well as pressurize the overall healthcare system with their pricing.
 

Genetic Analysis Market Analysis

Genetic analysis market from the carrier testing segment will register over 7.5% CAGR from 2022-2030. Carrier testing determines if a healthy person carries a recessive genetic disorder. The test offers life-long insights into the reproductive risk of an individual and the chances of having offspring with a genetic disorder. Advancements in carrier testing enable the identification of at-risk couples and carriers of disease genes. With the growing awareness about genetic disorders, the demand for genetic carrier testing for reproductive risk assessment will witness a steady increase.
 

Genetic analysis market from the infectious diseases segment is anticipated to reach USD 3 billion by 2030. Infectious diseases such as COVID-19 have varying impacts on different genomes. According to the UK Research and Innovation, men are more likely to be infected with COVID-19 than women due to the presence of only one X chromosome. There is a surging need for analysis of similar tests to address many other infection risks. The increasing burden of diseases will thus create high demand for urgent diagnosis and treatment tools, including genetic analysis.
 

Genetic analysis market value from the next-generation sequencing (NGS) technology is expected to depict over 8.5% CAGR between 2022-2030. Cancer has affected a significant amount of people across the world. As per the Cancer Atlas, the cancer burden is predicted to increase by more than 60% by 2040. NGS technology allows doctors to test multiple cancer-related genes simultaneously.
 

After the surgical removal of a patient’s tumor, the tumor tissues can be used for next-generation sequencing. In some cases, it is possible to study the blood sample of the patient to check if the disease has shed some tumor DNA in the bloodstream. Advantages such as this showcase the strong potential of NGS technology in genetic analysis of cancer patients.
 

Diagnostic centers segment will hold over 21.5% share of the global genetic analysis market by 2030. Early disease diagnosis enables patients to go through treatment at an earlier stage and mitigate disease severity which will reduce the mortality rate. In addition, the rising prevalence of acute disorders is amplifying the need for dedicated diagnostics centers with genetic testing facilities. These factors, along with global awareness regarding the importance of early disease diagnosis will generate lucrative growth opportunities for segment development.
 

Europe genetic analysis market is set to cross USD 3 billion by 2030. Growing R&D initiatives to advance genomic analysis has resulted in breakthrough discoveries in Europe. A notable example is research in genomics conducted by Swedish geneticist Svante Pääbo, which identified that gene transfer took place from now-extinct hominins to Homo Sapiens, after migrating from Africa close to 70,000 years ago. This gene flow also influences the physiology of the modern human population and is considered helpful in identifying measures to cure or avoid acute disorders. Such pathbreaking research projects are expected to create a favorable outlook for the genetic analysis industry in Europe.
 

Genetic Analysis Market Share

Some of the key players operating in the genetic analysis market include

• Thermo Fisher Scientific
• Abbott Laboratories
• PerkinElmer, Inc.
• BioRad Laboratories
• AutoGenomics Inc.
• ELITech Group
• IntegraGen
• Quest Diagnostics Inc.
• Hoffmann-La Roche AG
• Celera Group
• Qiagen
• Danaher (Cepheid)

Companies are receiving approvals for their new products, enabling them to extend their business operations and product portfolio.
 

Impact of COVID-19 Pandemic

Since the emergence of the COVID-19 outbreak, researchers and scientists have used genetic analysis to gain significant biological insights into the virus and the host factors that impact the immune system response. The SARS-CoV-2 virus had various mutations that resulted in deadly symptoms. Gene testing helped in identifying virus mutation which enabled rapid diagnosis and treatment.
 

This genetic analysis market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Billion from 2018 to 2030 for the following segments:

Click here to Buy Section of this Report

By Product

• Reagents & Kits
• Instruments
• Software

By Test

• Predictive Genetic Testing
• Carrier Testing
• Prenatal and Newborn Testing
• Disease Diagnostic Testing
• Pharmacogenomic Testing
• Others

By Application

• Cancer
• Genetic Diseases
• Cardiovascular Diseases
• Rare Diseases
• Infectious Diseases
• Others

By Technology

• Next-generation Sequencing (NGS)
• Real-Time PCR System
• Others

By End-use

• Hospitals
• Research & Development Laboratories
• Diagnostic Centers
• Others

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Netherlands
  • Switzerland
  • Others
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Indonesia
  • Singapore
  • Others
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Others
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Iran 
  • Others